Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Treatment Gaps for Patients With Metastatic CRC

July 27th 2021

Reactions to the increase in prevalence of metastatic colorectal cancer (CRC) among a younger patient population despite treatment advances.

Surgery Plus Neoadjuvant Therapy Improves Survival in Margin-Positive Pancreatic Cancer

July 26th 2021

Surgical resection demonstrated a notable survival benefit, particularly in combination with neoadjuvant therapy, in patients with aggressive margin-positive pancreatic cancer.

Biomarker Testing for Gastric and GEJ Cancers 

July 26th 2021

Experts in gastrointestinal oncology review the challenges associated with molecular testing and the role of biomarker testing on disease management. 

KEYNOTE-811: IO-Based Therapy for HER2+ Gastric Cancer

July 26th 2021

Sam Klempner, MD, and Daniel Catenacci, MD, discuss the KEYNOTE-811 study of pembrolizumab plus trastuzumab in combination with chemotherapy in patients with HER2-positive disease.

Bristol Myers Squibb Withdraws Single-Agent Nivolumab Post-Sorafenib HCC Indication in the United States

July 24th 2021

Bristol Myers Squibb has decided to voluntarily withdraw the indication for nivolumab as a monotherapy for patients with hepatocellular carcinoma who were previously treated with sorafenib from the US market.

Nivolumab Plus Chemo or Ipilimumab Represent Potential First-Line Standards in Advanced ESCC

July 21st 2021

Nivolumab plus chemotherapy or ipilimumab showcased superior overall survival over chemotherapy alone in previously untreated patients with advanced esophageal squamous cell carcinoma.

Pamrevlumab Plus Chemo Under Exploration in Novel Pancreatic Cancer Trial Platform

July 20th 2021

A new experimental treatment arm examining pamrevlumab in combination with gemcitabine and nab-paclitaxel as a first- or second-line treatment for patients with metastatic pancreatic cancer has been added to the novel clinical trial platform Precision Promise, which is being conducted by the Pancreatic Cancer Action Network.

Dr. Ma on First-Line Treatment Considerations in Metastatic Pancreatic Cancer

July 19th 2021

Wen Wee Ma, MBBS, discusses first-line treatment considerations in metastatic pancreatic cancer.

CHECKMATE649: Safety Profile and Toxicity Management

July 19th 2021

Thought leaders in gastric and GEJ cancers review safety outcomes from the CHECKMATE649 trial presented at the 2021 ASCO annual meeting.

CHECKMATE649: Trial Design and Efficacy Data

July 19th 2021

Key opinion leader in gastric cancer, Daniel Catenacci, MD, leads a discussion on the study design, patient population, and results from the CHECKMATE649 trial of nivolumab and chemotherapy in patients with gastric or GEJ cancers.

Wainberg Weighs In on Advances in HER2+ GI Cancers

July 12th 2021

Dr. Wainberg discusses factors that help steer treatment selection in HER2-positive gastrointestinal malignancies, advances on the horizon, and more.

Recent FDA Approvals in Gastric and GEJ Cancers

July 12th 2021

Daniel Catenacci, MD, and Sam Klempner, MD, consider the overall impact of recently approved immunotherapy-based regimens for gastric and gastroesophageal junction cancers.

Historical Perspective on Treatment of Gastric and GEJ Cancers 

July 12th 2021

Experts in the management of gastric cancer provide a historical perspective on available treatment options.

Bekaii-Saab Breaks Down Significant Developments in the Realm of Gastrointestinal Cancers

July 8th 2021

Tanios Bekaii-Saab, MD, spotlights the recent developments made in gastrointestinal cancers.

GI Cancer Armamentarium Gains Traction With Immunotherapy, Targeted Agents

July 7th 2021

Jimmy Hwang, MD, discusses the frontline indications for checkpoint inhibitors in gastric cancer and their effect on subsequent treatment decisions, the growth of targeted therapy across gastrointestinal cancers, and expectations for future research and development.

Novel Combination May Break Outcomes Stalemate in Pancreatic Cancer

July 7th 2021

Therapeutic breakthroughs for patients with metastatic pancreatic cancer have eluded investigators for decades, with chemotherapeutic combination strategies serving as the insurmountable standard of care.

Merck Withdraws Pembrolizumab Third-Line Gastric Indication in the United States

July 6th 2021

Merck has announced plans to withdraw the accelerated approval indication for pembrolizumab in the treatment of select patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express a PD-L1 combined positive score of 1 or more, and who have progressed on or after 2 or more previous lines of therapy, including fluoropyrimidine- and platinum-containing chemotherapy, and HER2-/neu-targeted therapy, if appropriate.

RWJBarnabas Health Pioneers Innovative Pancreatic Cyst Surveillance Program

July 5th 2021

The incidental identification of pancreatic cysts has become more common with the increasing use of imaging modalities in clinical practice.

GSK2636771/Paclitaxel Combo Demonstrates Early Promise in Advanced PTEN-Deficient Gastric Cancer

July 3rd 2021

The novel PI3Kß inhibitor GSK2636771 plus paclitaxel led to encouraging clinical activity as well as a tolerable safety profile in patients with PTEN-deficient advanced gastric cancer who progressed following frontline chemotherapy.

Tislelizumab, TTF Studies Poised to Address HCC Questions

July 2nd 2021

The optimal sequence of therapies in the second- or later-line settings for patients with hepatocellular carcinoma remains unclear.